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Abstract
Dengue disease is an increasing global health problem that threatens one-third of the world’s population. Despite decades
of efforts, no licensed vaccine against dengue is available. With the aim to develop an affordable vaccine that could be used
in young populations living in tropical areas, we evaluated a new strategy based on the expression of a minimal dengue
antigen by a vector derived from pediatric live-attenuated Schwarz measles vaccine (MV). As a proof-of-concept, we
inserted into the MV vector a sequence encoding a minimal combined dengue antigen composed of the envelope domain
III (EDIII) fused to the ectodomain of the membrane protein (ectoM) from DV serotype-1. Immunization of mice susceptible
to MV resulted in a long-term production of DV1 serotype-specific neutralizing antibodies. The presence of ectoM was
critical to the immunogenicity of inserted EDIII. The adjuvant capacity of ectoM correlated with its ability to promote the
maturation of dendritic cells and the secretion of proinflammatory and antiviral cytokines and chemokines involved in
adaptive immunity. The protective efficacy of this vaccine should be studied in non-human primates. A combined measles–
dengue vaccine might provide a one-shot approach to immunize children against both diseases where they co-exist.
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Introduction
Dengue fever is a mosquito-borne viral disease that threatens
the health of a third of the world’s population. During the last
twenty years, the four serotypes of dengue virus spread throughout
the tropics due to the presence of the mosquito vector Aedes aegypti
in all urban sites and to the major demographic changes that
occurred in these regions. This global re-emergence shows larger
epidemics associated with more severe disease [1]. Dengue is
a major worldwide public health problem with an estimated 100
million annual cases of dengue fever (DF) and 500,000 annual
cases of dengue hemorrhagic fever (DHF), the severe form of the
disease, resulting in about 25,000 fatal cases, mainly in children
under the age of 15. Although global prevention appears the best
strategy to control dengue expansion, there is still no licensed
vaccine available.
Dengue viruses (DV) are enveloped, positive-stranded RNA
viruses (Flaviviridae family). Four antigenically distinct viral
serotypes exist (DV1-4). The surface of virions is composed of
the major envelope glycoprotein (E) and a small membrane
protein (M). Very little information is available concerning the role
of the 75-amino acid long M protein. We previously reported that
ectopic expression of the 40-residue intraluminal ectodomain of M
(referred hereafter as ectoM) is able to induce apoptosis in
mammalian cells, suggesting that M might play an important role
in the pathogenicity of flaviviruses [2]. The envelope E protein,
which is exposed on the surface of viral particles, is responsible for
virus attachment and virus-specific membrane fusion. Anti-E
antibodies inhibit viral binding to cells and neutralize infectivity. A
primary DV infection is believed to induce life-long immunity to
the infecting serotype, while heterologous cross-protection against
other serotypes lasts only a few weeks, allowing re-infection by
another serotype. A number of clinical and experimental data
demonstrated the implication of the immune response in the
pathogenesis of severe forms of dengue, possibly through an
antibody-dependant enhancement (ADE) phenomenon based on
the cross-reactivity of DV antibodies [3,4]. The molecular
structure of the ectodomain of E glycoprotein has been determined
[5]. It is folded in three distinct domains I, II and III. The C-
terminal immunoglobulin-like domain III (EDIII) can be in-
dependently folded as a core protein through a single disulfide
bond and contains major serotype-specific neutralizing epitopes
PLoS Neglected Tropical Diseases | www.plosntds.org 1 2007 | Volume 1 | Issue 3 | e96[6]. On the opposite, epitopes inducing antibodies that cross-react
between serotypes have been located within the domain II, which
contains the fusion peptide [7]. Therefore, EDIII has emerged as
an antigen of choice to develop a dengue vaccine eliciting
serotype-specific rather than cross-reactive antibodies. Indeed,
recent studies have demonstrated that immunization with EDIII,
either encoded by a plasmid or as a recombinant protein in fusion
with a bacterial carrier, elicited neutralizing antibodies to DV
[8,9,10,11,12].
A preventive dengue vaccine needs to protect unexposed
individuals against all four serotypes of DV. It must be tetravalent,
safe for 9–12 months children and provide long-lasting protective
immunity. It must be produced at low cost and scaled up at million
doses. To address these challenges, we evaluated the immuno-
genicity of a live recombinant vector derived from pediatric
measles vaccine (MV) expressing a DV antigen designed to induce
neutralizing and non cross-reactive antibodies. MV vaccine is
a live-attenuated negative-stranded RNA virus proven to be one of
the safest, most stable, and effective human vaccines developed so
far. Produced on a large scale in many countries and distributed at
low cost through the Extended Program on Immunization (EPI) of
WHO, this vaccine induces life-long immunity after a single
injection [13,14,15] and boosting is effective. We previously
developed a vector derived from the live-attenuated Schwarz
strain of MV [16] that expressed stably different proteins from
HIV and induced strong and long-term specific humoral and
cellular immune responses [17,18]. Based on this approach
a program of clinical trials was initiated in collaboration with an
industrial vaccine manufacturer with funding from the EC, to
evaluate the safety and immunogenicity in humans of MV
encoding an HIV antigen. We also demonstrated that recombi-
nant MV could protect against flaviviruses, since MV expressing
the secreted form of the E protein from West Nile virus (WNV)
induced sterilizing humoral immunity against WNV in a mouse
model [19].
In the present work, we evaluated the immunogenic potential of
a MV vector expressing a DV1 soluble antigen composed of the
EDIII fused with the ectoM. In a mouse model of MV infection
this vector induced serotype-specific, virus-neutralizing antibodies
against DV1. Consistent with this observation, we showed that
infection of human monocyte-derived dendritic cells (DCs)
resulted in up-regulation of co-stimulatory molecules as well as
robust secretion of cytokines and chemokines that are identified as
playing a pivotal role in establishment of anti-viral immune
responses.
Materials and Methods
Cell culture
Vero (African green monkey kidney) cells were maintained in
DMEM-Glutamax (Gibco-BRL) supplemented with 5% heat-
inactivated fetal calf serum (FCS, Invitrogen, Frederick, MD).
Helper 293-3-46 cells (a gift from M. A. Billeter, Zurich Univer-
sity) used for viral rescue [20] were grown in DMEM/10% FCS
and supplemented with 1.2 mg of G418/ml. The human mono-
cytic cell line U937 (ATCC CRL 1593, American Type Culture
Collection, Rockville, Md.) was maintained in complete RPMI
(Gibco-BRL) supplemented with 10% FCS (Invitrogen), sodium
pyruvate, non-essential amino acids, penicillin G (100 IU/ml), and
streptomycin (100 mg/ml). Clinical-grade DCs were prepared as
described elsewhere [21,22]. DCs were maintained in AIMV
medium containing 500 U/mL GM-CSF (Gentaur, Brussels,
Belgium) and 50 ng/mL IL-13 (Peprotech, Tebu-bio, Rocky Hill,
NJ).
Construction of pTM-MVSchw-EDIII and pTM-MVSchw-
EDIII-ectoM plasmids
The plasmid pTM-MVSchw, which contains an infectious MV
cDNA corresponding to the anti-genome of the Schwarz MV
vaccine strain, has been described elsewhere [16]. The genomic
RNA of DV-1 strain FGA/89 [23] (Genbank accession number
AF 226687) was extracted from purified virions and reverse
transcribed using Titan One-Step RT-PCR kit (Roche Molecular
Biochemicals) according to the manufacturer’s instructions. The
coding sequence for PrM/E (amino acids 1-395) was cloned into
pMT/Bip/V5-His A plasmid (kindly provided by Erika Navarro-
Sanchez) and used as a template for further cloning. A PCR
fragment encoding the EDIII (aa 295-394) from the E protein was
amplified by High Fidelity Polymerase (PCR expand High
Fidelity, Invitrogen) using the forward primer 1EDIII 59-AATTA-
AGATCTAAAGGGATGTCATATGTGATGTG-39 containing
a BglII restriction site (underlined), and the reverse primer 2EDIII
59-TTAAGCGGCCGCTATCGCTTGAACCAGCTTAGTTTC-
39 containing a NotI restriction site (underlined) and a stop
codon (in bold). The sequence encoding the EDIII from the E
protein (aa 295-394) linked to the ectodomain of the membrane
M protein (aa 1-40) by the original furin-like cleavage site
RRDKR, was generated as follows. The FGA/89 EDIII
(Genbank accession no. AF 226687) was amplified using the
forward primer 1EDIII and the reverse primer 3EDIII 59-CGG-
AACGTTTGTCTCGTCGGAACCAGCTTAGTTTCAAAGC-39
containing the reverse complement sequence of the furin site of
the DV ectoM protein (underlined) and in 39 the reverse
complement sequence of the 39 EDIII end. The PCR product
was used as primer and template to amplify by a second PCR
the chimeric sequence EDIII-ectoM (Genbank accession no.
CS479843) using 1EDIII primer and the reverse primer 5EDIII
59-TTAAGCGGCCGCTATCATGGGTGTCTCAAAGCCCA-
AG-39 that contains a NotI restriction site (underlined) and a stop
codon (in bold). The cloned sequences respect the ‘‘rule of six’’,
which stipulates that the number of nucleotides into the MV
Author Summary
Dengue is a tropical emerging disease that threatens one-
third of the world’s population, mainly children under the
age of 15. The development of an affordable pediatric
vaccine that could provide long-term protection against all
four dengue serotypes remains a global public health
priority. To address this challenge, we evaluated a strategy
based on the expression of a minimal dengue antigen by
live attenuated measles vaccine (MV), one of the most safe,
stable, and effective human vaccines. As a proof-of-
concept, we constructed a MV vector expressing a secreted
dengue antigen composed of the domain III of the
envelope glycoprotein (EDIII), which contains major
serotype-specific neutralizing epitopes, fused to the
ectodomain of the membrane protein (ectoM) from DV-
1, as an adjuvant. This vector induced in mice durable
serotype-specific virus-neutralizing antibodies against DV1.
The remarkable adjuvant capacity of ectoM to EDIII
immunogenicity was correlated to its capacity to mature
dendritic cells, known to initiate immune response, and to
activate the secretion of a panel of cytokines and
chemokines determinant for the establishment of specific
adaptive immunity. Such strategy might offer pediatric
vaccines to immunize children simultaneously against
measles and dengue in areas of the world where the
diseases co-exist.
Measles-dengue Vaccine
PLoS Neglected Tropical Diseases | www.plosntds.org 2 2007 | Volume 1 | Issue 3 | e96genome must be a multiple of 6 [24]. A shuttle plasmid
(pTRE2-ssCRT) containing the human calreticulin signal
sequence was generated by transferring the calreticulin-derived
endoplasmic reticulum targeting signal sequence from the
pEGFP-RE vector (Clontech) to the pTRE2-Hyg plasmid
(Clontech). The DV-1 cDNAs were introduced into pTRE2-
ssCRT using BglII/NotI digestion. After sequencing, the 384 bp
coding for the EDIII and 516 bp coding for the EDIII-ectoM
antigens were inserted into BsiWI/BssHII-digested pTM-
MVSchw-ATU2, which contains an additional transcription
unit (ATU) between the phosphoprotein (P) and the matrix (M)
genes of the Schwarz MV genome [16,18,19]. The resulting
plasmids were designated as pTM-MVSchw-EDIII and pTM-
MVSchw-EDIII-ectoM.
Rescue of recombinant MV-EDIII and MV-EDIII-ectoM
from the cloned cDNA
Rescue of recombinant Schwarz MV from the plasmids
pTM-MVSchw-EDIII and pTM-MVSchw-EDIII-ectoM was
performed as previously described [16] using the helper-cell-based
rescue system described by Radecke et al [20] and modified by
Parks et al. [25]. The titers of MV-EDIII and MV-EDIII-ectoM
were determined by an endpoint limit-dilution assay on Vero cells.
The TCID50 was calculated by use of the Ka ¨rber method.
Production of recombinant EDIII and EDIII-ectoM
proteins in Drosophila S2 cells
The EDIII and EDIII-ectoM PCR products described above
were cloned into pMT/Bip/V5-His A plasmid (Invitrogen)
between BglII and NotI restriction sites. The clones were validated
by sequencing. Drosophila S2 cells (Invitrogen) were transfected by
these plasmids using the Calcium Phosphate Transfection Kit
(Invitrogen). Transfected cells were selected by adding 25 mg/ml
blasticidin. The EDIII and EDIII-ectoM protein production was
induced by adding 750 mM CuSO4. Cell culture supernatant was
filtered on 0.2 mM filters before concentration on 10,000-MWCo
Vivaspin columns (Vivasciences) eluted with PBS. Recombinant
proteins were semi-quantified by Western blot using the MAb
9D12 reactive to EDIII from DV [26].
Production of recombinant EDIII proteins in E. coli
The following DV strains from the collection of Institut Pasteur
were used: strain FGA/89 French Guiana for serotype DV1 [27],
Jamaica/N.1409 for DV2 [28], PaH881/88 Thailand for DV3
and 63632/76 Burma for DV4. The E. coli strain BL21(DE3) and
SB medium have been described [29]. Plasmids pLB11, pLB12,
pLB13, pLB14, coding respectively for EDIII from DV serotypes
1, 2, 3, 4 (residues 296-400) with an hexahistidine tag in C-term,
under control of the T7 promoter and pelB signal sequence, were
constructed by insertion of RT-PCR products obtained with
primers specific for EDIII, in plasmid pET20b+ (Novagen)
(O. Lisova et al., in preparation). The DV-EDIII-H6 recombinant
proteins were produced from these plasmids in E. Coli
BL21(DE3). Bacteria were grown at 24uC in SB medium with
ampicillin (200 mg/mL) until A600nm=1.5 to 2.0 and then induced
for 2.5 hours with 1 mM IPTG to obtain the expression of the
recombinant genes. The purification of DV-EDIII-H6 proteins
from bacteria’s periplasmic fluid was performed by chromato-
graphy on a NiNTA resin (Qiagen, Hilden) and concentration
determined by absorbance spectrometry as previously described
[30]. The protein fractions were analyzed by SDS-PAGE in
reducing conditions. The fractions that were homogeneous at
.95%, were pooled, dialyzed against 50 mM Tris-HCl, pH 8.0,
50 mM NaCl, snap frozen in liquid nitrogen, and stored at
280uC.
Synthetic ectoM peptide
A synthetic 40-residue long peptide corresponding to the ectoM
sequence from FGA/89 strain (SVALAPHVGLGLETRTET-
WMSSEGAWKQIQKV ETWALRHP) was synthesized with
a purity of at least 80% (Genecust, France).
Western blot assays
Protein lysates from Vero cells or U937 cells infected with
recombinant viruses were fractionated by SDS-PAGE gel electro-
phoresis and transferred to cellulose membranes (Amersham
Pharmacia Biotech). DV1 EDIII (5 ng) produced in drosophila
cells was loaded as a positive control. The blots were probed with
a murine monoclonal antibody mAb4E11 directed against the E
EDIII of DENV1 (Hybridoma cells producing 4E11 raised against
the envelope protein of DV1 were kindly provided by Dr Morens
[30]). A goat anti-mouse immunoglobulin G (IgG)-horseradish
peroxidase (HRP) conjugate (Amersham) was used as a secondary
antibody. Peroxidase activity was visualized with an enhanced
chemiluminescence detection kit (Pierce).
Apoptosis analysis
Cells were recovered by pipetting, centrifuged for 3 min at
1200 rpm, washed once in PBS and resuspended in FITC-labeled
annexinV/propidium iodide (PI) according to the manufacturer’s
instructions (Becton Dickinson, Apoptosis Detection kit). Labeled
cells were analyzed by flow cytometry using a FacsCalibur (BD
Biosciences, San Diego, CA), with CellQuest software (Becton
Dickinson, Lincoln Park, NJ). The percentage of apoptotic cells
was determined as the percentage of AnnexinV positive and
propidium iodide negative cells.
Immunofluorescence
Immunofluorescence staining was performed on infected cells,
as described elsewhere [31]. Cells were probed with mouse anti
DV-1 EDIII 4E11 antibody, mouse anti DV-1 HyperImmune
Ascitic Fluid [32] or rabbit anti human MHC-II dimer (kindly
provided by Neefjed J.) antibodies. Cy3-conjugated goat anti
mouse IgG antibody Cy3 conjugated (Jackson Immunoresearch
laboratories), FITC-conjugated goat anti-mouse IgG antibody
(Chemicon), or and FITC-conjugated goat anti-rabbit IgG anti-
body (Amersham Pharmacia Biotech) were used as secondary
antibodies respectively.
DC phenotypic analysis
Cell-surface staining was performed at 4uC for 30 minutes using
anti-CD86-PE (BD Pharmingen), CD83-APC (BD Pharmingen),
CD80-PE-Cy5 (Immunotech, Marseille) in 1% BSA and 3%
human serum-PBS. Isotype-matched mAbs were used as negative
controls. Labeled cells were analyzed by flow cytometry using
a FacsCalibur (BD), with FlowJo software (Tree Star, Ashland,
OR).
Detection of cytokines in DC supernatants
Supernatants were harvested after 16 h or 24 h of DC
incubation with MV-EDIII or MV-EDIII-ectoM at an MOI of
1. Aliquots of 200–300 ml were stored at 280uC. Production of
cytokines/chemokines was analyzed in 50 mL supernatant with
a human cytokine 25-plex antibody bead kit (Biosource, CA, WA,
cat. LHC0009) which measures IL-1a, IL-1Ra, IL-2, IL-2R, IL-4,
IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40/70, IL-13, IL-15, IL-17,
Measles-dengue Vaccine
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Eotaxin, RANTES and MCP-1 by using a Luminex 100
instrument (Luminex Corp., Austin, TX, USA).
Mice experiments
CD46-IFNAR mice susceptible to MV infection were produced
as previously described [16]. Mice were housed under specific
pathogen-free conditions at the Pasteur Institute animal facility.
Six-week-old CD46-IFNAR mice were inoculated intraperitone-
ally (i.p.) with 10
4 or 10
5 TCID50 of recombinant MV. Boosting
was performed using 10 mg of recombinant EDIII-ectoM protein
in Alugel adjuvant. To detect the anamnestic response generated
by immunization, immunized mice were i.p. inoculated with 10
7
FFU of live FGA/NA d1d variant of DV1 (Genebank accession
number AF 226686). This strain was previously generated by
adaptation of a clinical isolate to growth in newborn mouse brain
[23]. All experiments were approved and conducted in accordance
with the guidelines of the Office of Laboratory Animal Care at
Pasteur Institute.
ELISA for humoral responses
To evaluate the specific antibody responses, mice were bled via
the periorbital route at different time after inoculation. Sera were
heat inactivated at 56uC for 30 min and the presence of anti-MV
antibodies was detected by ELISA (Trinity Biotech). HRP-
conjugated anti-mouse immunoglobulin (Jackson Immuno Re-
search) was used as secondary antibody. Anti-DV antibodies were
detected by ELISA using 96-wells plates coated with either highly
purified FGA/89 DV1 particles, recombinant EDIII proteins from
DV1, DV2, DV3, DV4 produced in E. Coli. or synthetic ectoM
peptide. HRP-conjugated anti-mouse immunoglobulin was used as
secondary antibody. The endpoint titers of pooled sera were
calculated as the reciprocal of the last dilution giving twice the
absorbance of sera from MV inoculated mice that served as
negative controls.
Focus reduction neutralization test
Anti-DV neutralizing antibodies were detected by a focus
reduction neutralization test (FRNT) on Vero cells previously
described [19] using 50 FFU of Vero-adapted DV1 Hawaı ¨ (WHO
reference strain, Genbank accession no. AF226687), DV2 Jamaica
(Genbank accession no. M20558), DV3 H97 (WHO reference
strain, Genbank accession no. M93130) or DV4 63632. The
endpoint titer was calculated as the highest serum dilution tested
that reduced the number of FFU by at least 50% (FRNT50)o r
75% (FRNT75). For the neutralization tests in presence of recom-
binant EDIII or synthetic peptides ectoM peptides serum samples
were pre-incubated (in 50 ml medium) with 5 mg, 500 ng or 50 ng
of recombinant EDIII (produced in Drosophila S2 cells) or
synthetic ectoM peptide before performing FRNT.
Results
Recombinant viruses MV-EDIII and MV-EDIII-ectoM
express the EDIII antigen, lead to its secretion, and
replicate efficiently
We cloned from DV1 viral RNA the sequence encoding the
EDIII (E295-394) fused in C-term to the ectoM (M1-40), using as
a linker the original prM/M furin-like cleavage site RRDKR. This
combined dengue antigen was cloned downstream the cellular
calreticulin (ss-CRT) signal peptide sequence in order to allow the
disulfide bond formation and therefore the correct folding of
EDIII and to address the antigen in the secretion pathway. As
a control of proper folding and effective secretion of EDIII, we also
generated a similar construct without ectoM. The resulting ss-
CRT-EDIII-ectoM and ss-CRT-EDIII constructs were inserted
into MV vector (pTM-MVSchw plasmid), which contains an
infectious MV cDNA corresponding to the anti-genome of the
Schwarz MV vaccine strain [16] (Figure 1A). The recombinant
measles viruses MV-EDIII-ectoM and MV-EDIII were rescued
by transfecting the pTM-MVSchw-EDIII-ectoM and pTM-
MVSchw-EDIII plasmids into helper cells and propagation on
Vero cells, as previously described [16].
We analyzed the expression of DV antigens by recombinant
MV in infected Vero cells by immunofluorescence using a mono-
clonal neutralizing anti-DV1 EDIII antibody (4E11, [33]) and
anti-DV1 Hyper Immune Ascitic Fluid (HMAF) (Figure 1B). In
both cases, the antigens were clearly detected indicating that the
EDIII was expressed and that the epitope of 4E11 neutralizing
antibody was present and accessible. The presence of EDIII in
lysates and supernatants of infected Vero cells was further con-
firmed by Western blot using 4E11 antibody (Figure 1C). DV1
recombinant EDIII polypeptides (rEDIII and rEDIII-ectoM)
secreted from stable S2 cell lines were used as positive controls
(Figure 1D). DV1 EDIII antigen was detected both in lysates and
supernatants from cells infected by MV-EDIII-ectoM and MV-
EDIII vectors. The EDIII was clearly detected in unconcentrated
supernatant, despite that the supernatant volume was 100 times
larger than the lysate volume. Thus, secretion was efficient. The
intracellular EDIII shows a higher molecular weight on the
western blot than EDIII secreted in the supernatants, because of
the presence of the peptide signal, which was cleaved during
secretion. Similarly, the positive control (rEDIII from S2 cells) has
a higher molecular weight because it contains a poly-histidine tag.
Cells infected by MV-EDIII-ectoM produced cleaved EDIII and
uncleaved EDIII-ectoM antigens both in cell lysates and medium,
indicating that the furin-like cleavage site was accessible. Taken
together, these data show that MV-EDIII-ectoM vector is able to
produce secreted forms of EDIII, EDIII-ectoM, and by assump-
tion, ectoM (not detected because of the lack of specific antibodies
to ectoM).
We analyzed the replication of MV-EDIII-ectoM and MV-
EDIII viruses on Vero cells using the same MOI (0.01) than for
MV production. The growth kinetics of both recombinant viruses
were similar to that of control MV and the final titer was slightly
higher for MV-EDIII-ectoM (Figure 2A). We then investigated
whether the presence of ectoM in MV-EDIII-ectoM virus could
increase apoptosis of infected cells [2]. Since human monocytes
constitute a determinant target of MV infection for initiation of
immune responses, we addressed this question by infecting human
monocytic cells (U937 leukemic monocyte lymphoma cell line).
Growth kinetics of MV, MV-EDIII and MV-EDIII-ectoM in
U937 cells (MOI 1) show that these cells are permissive to MV
infection and that MV-EDIII-40 growth was slightly delayed as
compared to MV and MV-EDIII (Figure 2B). We quantified
apoptotic cells (annexin V positive/propidium iodide negative
cells) after infection at different MOI 0.1, 1 and 10. While we did
not observe apoptosis up to 42 hours post-infection when using
MOIs of 0.1 or 1 with the 3 viruses, increasing the MOI to 10 with
MV-EDIII-ectoM virus eventually induced apoptosis in 15% of
cells (Figure 2C). Apoptosis was related to the activation of caspase
3 pathway (not shown) and was dependent on virus replication,
since UV inactivated virus did not trigger apoptosis.
MV-EDIII-ectoM induces DV1 neutralizing antibodies in
mice
We examined the ability of MV-EDIII-ectoM recombinant
virus to raise specific anti-DV1 neutralizing antibodies in
Measles-dengue Vaccine
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mice express CD46, the human receptor for vaccine MV strains,
and lack the INF-a/b receptor (IFNAR) [16,18,35,36]. They have
previously been used as a model to evaluate the immunogenicity of
recombinant MV [16,17,18,19,36]. Six-week-old CD46-IFNAR
mice received two intraperitoneal (ip) injections within one month
of either 10
4 or 10
5 TCID50 of MV-EDIII-ectoM. As a control,
CD46-IFNAR mice were immunized with MV-EDIII and empty
Figure 1. Expression of DV1 EDIII and EDIII-ectoM by recombinant MV vector. (A) Schematic representation of DV1 EDIII and EDIII-ectoM
constructs and of recombinant MV vector. The human calreticulin peptide signal sequence (hCRT ps), the DV1 envelope E domain III (EDIII) and the M
ectodomain (ectoM) are indicated. Original furin-like cleavage site RRDKR and amino acid positions are indicated. The EDIII and EDIII-ectoM
sequences were cloned into the ATU position 1 of MV vector using BsiWI/BssHII sites. The MV genes are indicated as follows: nucleoprotein (N),
phosphoprotein and V/C accessory proteins (PVC), matrix (M) fusion (F), hemagglutinin (H) and polymerase (L). T7 RNA polymerase promoter (T7), T7
RNA polymerase terminator (T7t), hepatitis delta virus ribozyme (h), hammerhead ribozyme (hh). (B) Detection of DV1 EDIII in Vero cells infected for
24h with MV-EDIII or MV-EDIII-ectoM. EDIII was detected in two different experiments using either anti-EDIII 4E11 antibody (red label) or anti-DV1-
HMAF (green label). (C) DV1 EDIII expression in cell lysates (C) and supernatants (S) of Vero cells infected by MV-EDIII and MV-EDIII-ectoM analyzed by
western blot (cell lysates are 20 times more concentrated than supernatants). (+ ) positive control (5 ng of DV1 EDIII produced in drosophila S2 cells).
DV1 EDIII was probed with the 4E11 mouse monoclonal anti-DV1 EDIII. (D) Western blot analysis of recombinant rEDIII protein produced in E.coli
(100 ng) and recombinant rEDIII or rEDIII-ectoM proteins produced in drosophila S2 cells supernatants (0.5, 1 and 2 mg/well). DV1 EDIII was probed
with 4E11 mouse monoclonal anti-DV1 EDIII.
doi:10.1371/journal.pntd.0000096.g001
Figure 2. In vitro replication and cytopathic effects induced by recombinant MV-DV. (A, B) Growth kinetics of recombinant MV-EDIII and
MV-EDIII-ectoM viruses compared with standard MV on Vero and U-937 cells (MOI 0.01 and 1, respectively). Cell-associated virus titers are indicated in
TCID50. (C) Apoptosis of DCs infected by recombinant viruses (MOI 10). MV (triangles), MV-EDIII (squares), MV-EDIII-ectoM (open circles), mock
infected (diamonds). UV inactivated viruses (same symbols with dotted lines). The percentage of apoptotic cells represents the percentage of
Annexin-V positive and propidium iodide negative cells (determined using a flow cytometer). Values are means 6 SE from two independent
experiments, each performed in duplicate.
doi:10.1371/journal.pntd.0000096.g002
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one month after the second injection (Table 1). All immunized
mice raised antibodies to MV at similar titers. Specific anti-DV1
and anti-rEDIII antibodies were mounted in mice immunized with
MV-EDIII-ectoM (titers 3,000 and 10,000 respectively). Surpris-
ingly, no anti-DV antibodies were detected in sera of mice
immunized with MV-EDIII. An ELISA test using ectoM as coated
viral antigen showed that immune sera had no detectable levels of
anti-M antibodies. We evaluated the anti-DV1 neutralizing
activity of immune sera by using a focus reduction neutralization
test (FRNT) that allows to determine the highest serum dilutions
able to reduce by at least 50% or 75% the number of DV1 focus
forming units (FFU) on Vero cells. Again, whereas immunization
with MV or MV-EDIII did not induce neutralizing antibodies to
DV1, immunization by MV-EDIII-ectoM raised FRNT50 titers to
320 and FRNT75 titers to 40 (Table 1). Altogether, these data
show that EDIII-ectoM is able to elicit humoral immunity to DV.
Anamnestic response generated by immunization with
MV-EDIII-ectoM is strongly boosted by intraperitoneal
inoculation of live DV
Although CD46-IFNAR mice used in this study did not allow to
evaluate the protection conferred by immunization, we tested the
ability of live DV1 peripheral inoculation to stimulate long-term
anamnestic humoral response against MV-EDIII-ectoM. To assess
first the susceptibility of CD46-IFNAR mice to DV1 replication,
we inoculated mice intraperitoneally with 10
7 FFU of DV1 strain
FGA/NA d1d. No symptoms or mortality were observed and virus
replication could not be detected in mice serum by direct plaque
assay on mosquito cells (not shown). However, all groups of mice
seroconverted after live DV1 inoculation (Table 1). Interestingly,
the anamnestic memory induced by immunization with recombi-
nant MV-EDIII-ectoM was remarkably boosted by live DV1
inoculation, whereas animals immunized with MV-EDIII or
empty MV did not show any boost (Table 1). Both ELISA and
FRNT neutralizing titers against DV1 were strongly increased in
mice immunized with MV-EDIII-ectoM (30–100 times increase),
showing evidence of an efficient anamnestic response.
To test the longevity of this memory, another group of mice was
primed with two injections of MV-EDIII-ectoM vector (Table 2).
Six months later, they were boosted by injecting 5 mgo f
adjuvanted rEDIII-ectoM protein purified from supernatants of
transfected drosophila S2 cells. Protein boost increased the
neutralizing titer from 10 to 200. However, the titer decreased
rapidly to 40, indicating a transient boost. As a control, mice
inoculated only with the recombinant protein remained negative
even after three injections (not shown). At 9 months post priming,
mice were i.p. inoculated with 10
7 FFU of live FGA/NA d1d
DV1. One month after DV1 inoculation, we again observed a 100
times increase in the level of antibodies to DV1 and to EDIII as
Table 1. Antibody response of CD46-IFNAR mice to immunization with MV-EDIII or MV-EDIII-ectoM.
Injections MV Ab titer
c DV1 Ab titer
c rEDIII Ab titer
c ectoM Ab titer
c Anti-DV1 FRNT50
d Anti-DV1 FRNT75
e
MV
a 100,000 ,100 ,100 ,100 ,10 ,10
DV1
b 10,000 3,000 1,000 ,100 320 160
MV-DIII
a 100,000 ,100 ,100 ,100 ,10 ,10
DV1
b 10,000 3,000 1,000 ,100 320 160
MV-EDIII-ectoM
a 100,000 3,000 10,000 ,100 320 40
DV1
b 10,000 30,000 300,000 ,100 8000 2560–5120
aCD46-IFNAR mice were inoculated intraperitoneally (i.p.) twice with 10
5 TCID50 of MV, MV-EDIII or MV-EDIII-ectoM at one month of interval (6 mice/group).
bTwo
months after the last immunization, mice were inoculated with 10
7 FFU of DV1 FGA/NA d1d and sera were analyzed 3 weeks after.
cAntibody titers were determined by
ELISA on pooled heat-inactivated sera collected one month after immunization and DV inoculation.
dFRNT50 represents the highest serum dilution that reduced the
number of DV focus-forming units (FFU) on Vero cells by at least 50% and
eFRNT75 by at least 75%.
doi:10.1371/journal.pntd.0000096.t001
Table 2. Long-term antibody response of CD46-IFNAR mice to immunization with MV-EDIII-ectoM.
Injections
a (time, months)
Time of sera collection
(months) MV Ab Titer
b DV-1 Ab Titer
b
DV-1 rEDIII
Titer
b
Anti-DV1
FRNT50
c
Anti-DV1
FRNT75
d
MV-EDIII-ectoM (0) 1 15,000 ,100 # 100 nd nd
MV-EDIII-ectoM (1) 2 40,000 1,600 400 40 10
3 30,000 1,000 600 40 10
5 20,000 500 100 40 10
rEDIII-ectoM (6) 7 20,000 20,000 100,000 1600 200
9 10,000 2,000 10,000 320 40
DV1 inoculation (9) 10 10,000 200,000 800,000 32,000 4,000
aCD46-IFNAR mice were inoculated intraperitoneally (i.p.) twice with 10
4 TCID50 of MV-EDIII-ectoM at one month of interval. At 6 months, mice were boosted with 10 mg
of recombinant DV1 rEDIII-ectoM protein (from S2 cells) in Alugel adjuvant. At 9 months, mice were inoculated with 10
7 FFU of DV-1 FGA/NA d1d.
bDetermined by
ELISA on pooled heat-inactivated sera collected one month after immunizations or DV infection.
cFRNT50 represents the highest serum dilution that reduced the
number of DV focus-forming units (FFU) on Vero cells by at least 50% and
dFRNT75 by at least 75%.
doi:10.1371/journal.pntd.0000096.t002
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that neutralizing antibodies to DV EDIII induced by MV-EDIII-
ectoM are efficiently boosted upon live DV exposure 9 months
after priming, and demonstrates the induction of a durable B-cell
memory. However, the protection against DV infection needs to
be evaluated in a more appropriate non-human primate model.
Anti-DV1 neutralizing antibodies raised by MV-EDIII-
ectoM immunization are specific of DV1-EDIII and do not
cross-react with other serotypes
To assess the DV serotype specificity of antibodies induced, we
tested mice sera from experiment presented in table 2 by ELISA
against rEDIII proteins from DV1, 2, 3 and 4, respectively. We
also evaluated the anti-DV1, anti-DV2, anti-DV3 and anti-DV4
neutralizing activity of immune sera by FRNT50. Antibodies
induced by recombinant MV-EDIII-ectoM were specific to DV1
and did not cross-react with the EDIII from the other serotypes of
DV (Table 3). This confirms that EDIII antigenic surface is
serotype specific. To determine whether the antiviral neutralizing
activity induced by MV-EDIII-ectoM was specifically directed
against the EDIII, even after live DV1 inoculation, we performed
neutralization tests in presence of increasing concentrations of
either rEDIII protein produced in drosophila cells or synthetic
ectoM peptide (Figure 3). Increasing concentrations of rEDIII
protein strongly reduced the antiviral activity of sera collected
before and after live DV1 inoculation, whereas ectoM peptide was
ineffective. This experiment demonstrates that the neutralizing
antibodies induced by immunization were specifically directed
against EDIII epitopes essential for virus infectivity. Moreover, the
antiviral activity of sera collected after live DV1 inoculation was
also completely inhibited by rEDIII protein, indicating that live
DV1 inoculation increased the level of antibodies already induced
by immunization, but did not raise new antibodies directed to
other neutralizing epitopes than EDIII.
Altogether, these experiments demonstrate that recombinant
MV-EDIII-ectoM virus induced specific antibodies to DV1 EDIII
that did not cross-react with other DV serotypes and that
neutralized specifically DV1 infection. The EDIII alone expressed
by recombinant MV was poorly immunogenic, although it was
expressed and secreted at levels similar to EDIII-ectoM. The
presence of the ectoM was determinant to its immunogenicity,
raising the question of the mechanism of this effect. Does the
presence of ectoM in C-term of the EDIII sequence improve the
conformation of EDIII to make it biologically active, or adjuvant
its immunogenicity through an indirect mechanism? The EDIII
secreted from cells infected by MV-EDIII was recognized by
neutralizing antibody 4E11, which binds to the active receptor-
binding form of EDIII [33] The same EDIII sequence secreted by
drosophila cells was able to efficiently compete with the neutraliz-
ing activity of antibodies induced by the MV-EDIII-ectoM virus,
thus suggesting that EDIII was biologically functional, at least able
to present neutralizing epitopes. To address the question of
adjuvantation, we compared in vitro the effect of MV-EDIII-ectoM
and MV-EDIII infection on human immature monocyte-derived
DCs (MDDCs) in terms of activation/maturation and cytokine/
chemokine secretion.
MV-EDIII-ectoM replication enhances maturation of DCs
and cytokine/chemokine secretion
Upon virus infection, immature dendritic cells (DCs) undergo
maturation, and transport the virus to regional lymph nodes,
where viral antigens are presented to lymphocytes to initiate
immune response [37]. DCs are permissive to MV infection [38]
leading to the up-regulation of co-stimulatory molecules
[39,40,41]. To evaluate in vitro the effect of recombinant MV-
DV on DC activation, we cultivated human immature monocyte-
derived DCs (MDDCs) in presence of MV-EDIII-ectoM or MV-
EDIII viruses. After 17 hours of infection, DCs expressed the DV1
EDIII as detected by immunofluorescence (Figure 4). We then
analyzed the kinetics and levels of expression of costimulatory
molecules on the surface of DCs. The three viruses MV-EDIII-
ectoM, MV-EDIII and MV promoted the up-regulation of CD86,
CD83 and CD80 molecules as compared to mock-treated DCs
(Figure 5). Remarkably, MV-EDIII-ectoM up-regulated these
molecules more extensively and at earlier time points than MV-
EDIII and MV. Viral replication and de novo synthesis of EDIII-
Figure 3. Neutralization tests in presence of recombinant rEDIII
protein or synthetic ectoM peptide. The neutralization activity of
immune sera collected before DV exposure (diamonds and triangles, 1/
100 dilution) and post DV exposure (open squares 1/1000 dilution) was
tested in presence of increasing doses of recombinant EDIII (produced
in drosophila cells) or ectoM synthetic peptide. Pools of sera were
preincubated with rEDIII or ectoM for 1h at 37uC before FRNT75 titration
on Vero cells (50 FFU DV1 FGA89 for 2h at 37uC).
doi:10.1371/journal.pntd.0000096.g003
Table 3. Serotype specificity of antibodies induced in CD46-IFNAR mice after immunization with recombinant vectors.
DV1 DV2 DV3 DV4
Ab titer
a FRNT50
b Ab titer
a FRNT50
b Ab titer
a FRNT50
b Ab titer
a FRNT50
b
MV 3,000 160 ,100 nd ,100 nd ,100 nd
MV-EDIII 3,000 160 ,100 40 ,100 40 ,100 40
MV-EDIII-ectoM 300,000 10240 500 40 ,100 20 ,100 10
aDetermined by ELISA using plates coated with rEDIII from DV1, 2, 3 or 4 produced in E. coli (pooled heat-inactivated post-DV inoculation sera from experiment
presented in Table 2).
bFRNT50 is the highest serum dilution that reduced the number of DV focus-forming units (FFU) on Vero cells by at least 50%.
doi:10.1371/journal.pntd.0000096.t003
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synthetic ectoM peptide had no effect (not shown). To determine if
the increased capacity of MV-EDIII-ectoM to activate DCs
correlated with phenotypic functional changes, we analyzed the
secretion of 23 cytokines/chemokines in the supernatant of DCs
cultivated for 16h and 24h in presence of MV-EDIII-ectoM or
MV-EDIII. As a control, DCs were mock-infected or cultivated in
presence of LPS. We found that infection with MV-EDIII or
MV-EDIII-ectoM induced a panel of cytokines and chemokines
consistent with other reports on DC infection by MV (Table 4)
[42]. Remarkably, some cytokines and chemokines were signifi-
cantly enhanced and/or induced at earlier time points by MV-
EDIII-ectoM as compared to MV-EDIII (Table 4, Figure 6).
Among them, IFN-a (1000 pg/ml at 16 h), IL1RA (750 pg/m),
IL4 (13 pg/m) and the proinflammatory cytokines IL-6
(1250 pg/m) and TNF-a (1700 pg/m) were induced much more
rapidly after MV-EDIII-ectoM infection and at levels 8–10 times
higher than after MV-EDIII infection (Figure 6). Such a strong
enhancement in production of these cytokines is expected to
accelerate the establishment of immune response and to favor
humoral immunity. Similarly, remarkable levels of MIP-1a
chemokine were induced by MV-EDIII-ectoM at early time
points (9,000–20,000 pg/ml). A similar robust and early secretion
was observed for RANTES, MIP-1b and MCP-1a. The pro-
duction of these chemokines by maturing DCs may promote the
recruitment of other antigen presenting cells (APC) such as
immature DCs to enhance and sustain antigen sampling, and
polarization of the immune response [43,44,45]. Thus, adding the
ectoM protein in fusion with EDIII resulted in a stronger and
faster maturation of human DCs and activated the secretion of
higher levels of inflammatory and antiviral cytokines as well as
chemokines determinant for the establishment of specific immune
responses.
Discussion
The objective of this study was to evaluate the immunogenicity
of a dengue vaccine candidate based on a pediatric measles
vaccine expressing a minimal dengue antigen. This strategy
provides a recombinant vaccine that might protect children
Figure 5. Expression of CD86, CD80, CD83 cell surface molecules on human DCs incubated in presence of MV-EDIII and MV-EDIII-
ectoM (MOI of 1), or mock treated. The expression of cell surface markers was analyzed after 15h and 24h incubation by flow cytometry. Data
shown are representative of three individual experiments. Thin light-grey line represent staining of mock-treated DC, dashed grey lines represent
staining of MV-EDIII-infected DCs, and thick black line represent staining of MV-EDIII-ectoM-infected DCs.
doi:10.1371/journal.pntd.0000096.g005
Figure 4. Detection of DV1 EDIII in human DCs incubated for 17h with MV-EDIII or MV-EDIII-ectoM (MOI 1). EDIII was detected using
anti-EDIII 4E11 antibody (red label). Anti-human MHC-II dimer primary antibody was used as a DC marker (green label) (kindly provided by Neefjed J.).
Cells nuclei were labeled with DAPI.
doi:10.1371/journal.pntd.0000096.g004
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affordable to populations through the EPI program in the regions
affected both by dengue and measles infections. An efficient
pediatric dengue vaccine is supposed to elicit durable protective
humoral immune responses against all four dengue serotypes
without risk of ADE [46]. Regarding this objective, we assembled
covalently the antigenic domain III from the DV1 envelope E
glycoprotein and the pro-apoptotic ectodomain of DV-1 M
protein to generate a dengue combined antigen, EDIII-ectoM.
In the fusion construct, the N-terminal calreticulin peptide signal
sequence directs EDIII-ectoM to the secretory pathway. The
furin-dependent cleavage site of prM/M which links ectoM to
EDIII allows the processing of the antigen by specific proteases
throughout the Golgi apparatus. Expressed by recombinant MV
vector, the EDIII-ectoM antigen induced in mice susceptible to
MV specific antibodies to DV1 EDIII that did not cross-react with
other DV serotypes and that neutralized DV1 infection in vitro.
Immunization primed a long-term memory that was vigorously
boosted when animals were inoculated with live DV.
Although DV disease pathogenesis and protection mechanisms
are not fully clarified, disease severity is correlated with viremia
levels and neutralizing antibody is generally used as a marker of
vaccine effectiveness [47]. Experimental mouse models of DV
infection have been reported showing that adult AG129 mice,
which are deficient for IFN a/b/c receptors develop a dose-
dependant transient viremia after peripheral injection of
unadapted or mouse-adapted DV, whereas A129-IFNAR mice,
which are deficient only for IFN-a/b receptor are less sensitive to
DV infection [48,49,50]. However, AG129 mice are not sensitive
to MV infection and the prototype DV1 Hawaı ¨ strain did not
replicate in these mice [50]. Suckling mice develop lethal
encephalitis after DV intracerebral inoculation, but in our study
mice were 3–4 month-old after two MV immunizations and
intracranial inoculation could not be performed. Moreover, this
model is far from the human situation since DV does not infect the
nervous system, nor lead to encephalitis in humans. The CD46-
IFNAR mouse model sensitive to MV infection that we used did
not allow documenting in vivo protection from DV replication.
Therefore, to demonstrate the induction of anamnestic neutraliz-
ing antibody response upon live DV exposure, mice were
peripherally inoculated with DV a long time after immunization.
These experiments showed that neutralizing antibodies induced by
immunization with MV-EDIII-ectoM were strongly boosted by
live DV inoculation, thus suggesting a protective capacity. Indeed,
the available vaccines against yellow fever, Japanese encephalitis
and tick-borne encephalitis viruses have proven that anamnestic
neutralizing antibodies play an essential role for protection against
flaviviral infections [47].
The EDIII without ectoM was poorly immunogenic in the
context of MV expression. It appeared, therefore, that the 40-
residue long ectodomain of M plays a critical role in its
immunogenicity. DV EDIII has been previously shown to be
immunogenic in the form of recombinant chimeric proteins
[8,9,10,12] or expressed from a plasmid [51] or from adenovirus
vector [52,53]. To determine whether the EDIII sequence inserted
into MV vector was able to present neutralizing epitopes, we
produced in E.coli recombinant EDIII proteins from DV1, 2, 3
and 4 corresponding to the same sequence and we coated plates
with these proteins. Tested by ELISA on these plates, a neutral-
izing HMAF specific to DV1 recognized specifically the DV1-
EDIII, but not the other serotypes (data not shown), indicating its
specificity. This DV-1 HMAF recognized also specifically by
immunofluorescence the DV1 EDIII expressed in cells infected by
MV-EDIII, indicating the capacity of EDIII to expose serotype-
specific epitopes. The neutralizing monoclonal antibody 4E11
recognized also the EDIII expressed by MV-EDIII infected cells,
indicating that the epitope specific of this antibody is accessible
within the EDIII expressed by MV. This epitope has been mapped
and shown to be exposed on the native form of EDIII [33].
Furthermore, we expressed the same EDIII sequence as a secreted
protein by drosophila cells and showed that it was able to
efficiently compete with the neutralizing activity of antibodies
induced by the MV-EDIII-ectoM virus. Altogether, these
observations suggest that EDIII expressed by MV was able to
present a conformationally active neutralizing epitope. Recent
studies evaluating the immunogenicity of West-Nile virus (WNV)
EDIII showed that a high amount of EDIII was necessary to
induce neutralizing antibodies, while EDIII fused to TLR ligands
was immunogenic and conferred protection at lower doses
[54,55]. Therefore, the low immunogenicity of DV EDIII in
our hands might be due to the lower amount of antigen expressed
by recombinant MV as compared to the high protein or DNA
doses administered by others. To increase the level of expression
by MV, EDIII can be cloned upstream the N gene, as MV genes
are expressed as a gradient from the 39 to the 59 end of the
genome.
Table 4. Cytokine and chemokine secretion induced in
human DCs by MV-EDIII and MV-EDIII-ectoM.
MV-EDIII MV-EDIII-ectoM
IL-1b --
IL2 - -
IL5 - -
IL10 - -
INFc --
Eotaxin - -
IL7 ++
IL8 ++ ++
IL12p40-70 ++
IL15 ++
IL17 ++
IL1-RA + +++
IL2R ++ +
IL4 + +++
IL6 + +++
TNFa ++ +
INFa + +++
MCP-1 + +++
MIG ++ +
MIP-1a + +++
MIP-1b + +++
IP10 ++ +
RANTES + +++
Cytokine/chemokine production determined by multiplex assay in supernatants
of human DCs incubated in presence of MV-EDIII or MV-EDIII-ectoM (16h
incubation). Results are from four independent experiments performed with
four different donors. Production levels are indicated as :
(-) basal production by mock-treated DCs
(+) less than twofold increase compared to mock-treated DCs
(++) more than threefold increase compared to mock-treated DCs
(+++) more than fourfold increase compared to mock-treated DCs
doi:10.1371/journal.pntd.0000096.t004
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four serotypes of DV, has pro-apoptotic properties [2]. High titers
of MV-EDIII-ectoM induced apoptosis of infected U937 mono-
cyte-like cells that was not observed at standard titers. This critical
point in terms of safety needs to be evaluated further in the
development of this vaccine candidate. Indeed, recombinant MV
vector has to keep the high safety level of standard MV vaccine.
However, this property might be determinant to the immunoge-
nicity of EDIII because apoptotic infected cells express Toll-like
receptor (TLR) ligands that increase the cross-presentation of viral
epitopes by antigen presenting cells [56,57]. Indeed, we observed
that ectoM, in the context of MV replication, increased human
DCs maturation and triggered the release of cytokines and
chemokines determinant for the establishment of specific adaptive
immunity. Therefore, its capacity to adjuvant EDIII might be still
more efficient in humans than in CD46-IFNAR mice. Further
studies are needed to address the mechanism of action at the
molecular level.
In conclusion, we have produced a minimal antigen from DV1
able to induce long-term specific neutralizing antibodies to DV1
with no cross-reactivity with other serotypes. We have shown that
the remarkable adjuvant capacity of ectoM to EDIII immunoge-
nicity was correlated to its capacity to mature primary DCs and to
activate the secretion of a panel of proinflammatory and antiviral
cytokines, as well as numerous chemokines determinant for the
establishment of specific adaptive immunity. The immunogenicity
of this antigen was demonstrated through its expression by
a recombinant MV vector, thus making the proof-of-concept of
this strategy for dengue vaccine development. Using MV as
a vaccination vector presents a number of advantages : vaccination
against measles is mandatory, vaccine strains are genetically stable,
MV does not recombine or integrate genetic material, and vaccine
does not persist or diffuse. MV-specific CD8 T cells and IgG are
detected in vaccinees up to 25–34 years after a single MV
vaccination [14] and boosting increases this memory [15]. Using
MV as a recombinant vaccine to immunize simultaneously against
measles and dengue might be particularly attractive in areas where
both diseases threaten children every year, such as Africa and
South America. Taking advantage of the capacity of MV vector to
express large amounts of heterologous genetic material very stably
[58], we generated tetravalent dengue antigenic constructs
inserted into single MV vectors that are currently characterized.
Such a strategy should avoid the stability and interference pro-
blems encountered with tetravalent formulation of four attenuated
viruses, as well as the reactogenicity problems [59]. These new
candidates will be evaluated in a much more appropriate non-
human primate model.
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Figure 6. Cytokine and chemokine secretion by human DC incubated in presence of MV-EDIII and MV-EDIII-ectoM (MOI 1). The
supernatants harvested at 16h (white bars) and 24h (black bars) after infection were analyzed with a multiplex assay to measure the concentration of
cytokines and chemokines. The values are means 6 SE from four independent experiments.
doi:10.1371/journal.pntd.0000096.g006
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